Invicta Diagnostic Ltd
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions [1]
- Market Cap ₹ 101 Cr.
- Current Price ₹ 80.4
- High / Low ₹ 105 / 58.1
- Stock P/E 18.8
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 56.9 %
- ROE 44.4 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of Nifty SME Emerge
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 3.50 | 16.27 | |
| 2.03 | 9.88 | |
| Operating Profit | 1.47 | 6.39 |
| OPM % | 42.00% | 39.27% |
| 1.34 | 1.46 | |
| Interest | 0.01 | 0.03 |
| Depreciation | 0.38 | 0.95 |
| Profit before tax | 2.42 | 6.87 |
| Tax % | 0.83% | 21.54% |
| 2.40 | 5.38 | |
| EPS in Rs | 182.51 | 6.39 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 365% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 124% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 44% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 0.13 | 8.42 |
| Reserves | 9.30 | 6.39 |
| 0.00 | 0.00 | |
| 1.63 | 2.68 | |
| Total Liabilities | 11.06 | 17.49 |
| 4.59 | 3.85 | |
| CWIP | 0.00 | 0.00 |
| Investments | 4.20 | 8.00 |
| 2.27 | 5.64 | |
| Total Assets | 11.06 | 17.49 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 5.05 | 4.13 | |
| -9.51 | -4.22 | |
| 5.35 | 0.00 | |
| Net Cash Flow | 0.89 | -0.08 |
| Free Cash Flow | 0.08 | 3.92 |
| CFO/OP | 344% | 88% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 74.04 | 53.62 |
| Inventory Days | 378.04 | 94.53 |
| Days Payable | 977.68 | 73.53 |
| Cash Conversion Cycle | -525.60 | 74.62 |
| Working Capital Days | -1.04 | 48.91 |
| ROCE % | 56.93% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Average Revenue per Test (ARPT) INR |
|
||
| Number of Institutional Clients Number |
|||
| Pathology Tests Performed Number |
|||
| Radiology Tests Performed Number |
|||
| Total Diagnostic Centres Number |
|||
| Total Patients Served Number |
|||
| Total Tests Performed Number |
|||
| Average Revenue per Patient INR |
|||
Extracted by Screener AI
Documents
Announcements
-
Shareholders meeting
18 April 2026 - EGM held on 17 April 2026; shareholders approved WTD finance appointment and four material related-party transactions.
-
Shareholders meeting
17 April 2026 - On 17 Apr 2026, EGM approved IPO object changes, extension, related-party transactions, and Rohit Srivastava as WTD Finance.
-
Structural Digital Database
14 April 2026 - Submitted compliance certificate for year ended March 31, 2026 under PIT Regulations.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
14 April 2026 - Quarterly corporate governance report filed; Regulation 27(2) not applicable on NSE Emerge SME exchange.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
14 April 2026 - Regulation 74(5) certificate filed for quarter ended March 31, 2026; no dematerialisation requests received.
Business Profile[1]
PC Diagnostics (Invicta) is a diagnostic chain in the Mumbai Metropolitan Region (MMR) offering radiology and pathology services. The company operates 7 diagnostic centres + 1 centralised laboratory, built on a hub-and-spoke model.